Calidi Biotherapeutics And City Of Hope Announce Funding Of $5.3M From The California Institute For Regenerative Medicine To Advance CLD-101 (Neuronova) In Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics and City of Hope have received a $5.3M grant from the California Institute for Regenerative Medicine to advance their CLD-101 (Neuronova) treatment for ovarian cancer. This funding aims to support the development and potential commercialization of CLD-101, a promising therapeutic option for ovarian cancer patients.
March 11, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics, involved in the development of CLD-101 (Neuronova) for ovarian cancer, has received a $5.3M grant from the California Institute for Regenerative Medicine. This funding is expected to accelerate the development and potential market entry of CLD-101, enhancing Calidi's position in the biotechnology sector.
The $5.3M grant from the California Institute for Regenerative Medicine to Calidi Biotherapeutics for advancing CLD-101 (Neuronova) in ovarian cancer is a significant positive development. It not only provides financial resources but also validates the potential of CLD-101. This funding is likely to accelerate the development process, potentially leading to quicker commercialization. Given the specificity of the news to Calidi Biotherapeutics and its direct impact on one of its key projects, the news is highly relevant and important for investors, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100